| Literature DB >> 27465301 |
Sarrah Ayuandari1,2, Katharina Winkler-Crepaz3, Monika Paulitsch1,4, Cora Wagner1, Claudia Zavadil5, Claudia Manzl5, Stephanie C Ziehr1,6, Ludwig Wildt1, Susanne Hofer-Tollinger1.
Abstract
PURPOSE: To study the influence of xenotransplantation on follicular recruitment and growth in cryopreserved/thawed human ovarian tissue.Entities:
Keywords: Fertility preservation; Follicular recruitment; Human ovarian tissue cryopreservation; Human ovarian tissue xenotransplantation; PTEN
Mesh:
Substances:
Year: 2016 PMID: 27465301 PMCID: PMC5171895 DOI: 10.1007/s10815-016-0769-2
Source DB: PubMed Journal: J Assist Reprod Genet ISSN: 1058-0468 Impact factor: 3.412
Patients’ characteristics
| No. | Diagnosis | Age at cryopreservation | AMH prior to surgery (μg/l) | Chemotherapy prior to surgery (Y/N) |
|---|---|---|---|---|
| 1 | Morbus Hodgkin | 26 | 1.06 | N |
| 2 | Breast Cancer | 33 | 2.66 | N |
| 3 | Morbus Hodgkin | 22 | Not applicablea | N |
| 4 | Breast cancer | 33 | 0.86 | N |
| 5 | Breast cancer | 27 | 2.14 | N |
| 6 | Morbus Hodgkin | 27 | 1.62 | Y |
| 7 | Breast Cancer | 39 | <0.17 | N |
| 8 | ALL | 20 | 2.66 | Y |
| 9 | B-NHL | 22 | 0.33 | Y |
| 10 | AML | 23 | <0.17 | Y |
| 11 | NHL | 25 | 2.70 | N |
In 10 out of 11 patients, AMH levels were measured before the laparoscopical retrieval of ovarian tissue for cryopreservation. Seven patients did not receive chemotherapy before ovarian tissue cryopreservation and four patients received chemotherapy before ovarian tissue cryopreservation. In one patienta, AMH level (<0.17 μg/l) was determined after the surgery and after the first cycle of chemotherapy
Fig. 1Follicles were classified and counted in pregraft control, 4-week grafts, and 12-week grafts. Total follicles per biopsy as well as percentages of primordial, primary, and secondary follicles are presented in mean ± SEM. Antral follicles are not represented in the figure and the table because they formed only 0.49 % (5/1014) of all follicles observed. a Significant differences between the two observation periods and pregraft control (P < 0.05). b Significant differences between 4 and 12 weeks of grafting (P < 0.05)
Percentage of Ki67 positive follicles in pregraft controls, 4-week grafts, and 12-week grafts
| Follicle stage | Pregraft | 4 weeks | 12 weeks |
|---|---|---|---|
| Primordial | 10.28 % | 70.83 %a | 70.59 %a |
| (11/107) | (17/24) | (12/17) | |
| Primary | 18.18 % | 50 % | 72.73 %a |
| (2/11) | (3/6) | (8/11) | |
| Secondary | – | 100 % | 100 % |
| – | (4/4) | (14/14) | |
| Antral | – | – | 100 % |
| – | – | (2/2) | |
| Total Ki67 positive follicles | 11.02 % | 70.59 %a | 81.82 %a |
| (13/118) | (24/34) | (36/44) |
Percentage of primordial, primary, secondary, and antral follicles showing Ki67 immunostaining in pregraft controls and after 4 and 12 weeks of grafting, respectively. The total number of Ki67-positive follicles as well as the total number of all analyzed follicles are given in brackets
aSignificant difference between the two observation periods compared to the pregraft control (P < 0.05)
Fig. 2Relative expression of the PTEN gene after xenotransplantation compared to pregraft control. Figure shows 2.47-fold reduction of the PTEN gene expression after 4 weeks of grafting. This difference reached significance when 2−ΔCt were analyzed. Data are presented in mean ± SEM